Wednesday, Jan 17, 2007
South San Francisco, Calif. -- January 17, 2007 --Genentech, Inc. (NYSE: DNA) today announced the promotions of four vice presidents to senior vice president and the appointment of a new vice president. The four vice presidents promoted to senior vice president include: Markus Gemuend, senior vice president, Biochemical Manufacturing; Sean A. Johnston, senior vice president and general counsel; Timothy L. Moore, senior vice president, Global Supply Chain; and John Orwin, senior vice president, Sales and Marketing, BioOncology. Also announced was the promotion of Christopher Horan to vice president, Planning, Distribution and Logistics (formerly known as Supply Chain Management).
Senior Vice President Promotions
Senior Vice President, Biochemical Manufacturing
Markus Gemuend has been promoted to senior vice president, Biochemical Manufacturing, reporting to Patrick Y. Yang, Ph.D., executive vice president, Product Operations. In this newly created role, Gemuend is responsible for all of Genentech's biochemical manufacturing of bulk product.
Gemuend joined Genentech in 2004 as vice president, Manufacturing Collaborations and Contract Manufacturing. Prior to joining Genentech, he spent 16 years at Lonza Group, Ltd., where he served as chief executive officer from 2002 to 2004. While at Lonza, Gemuend held several other leadership roles, including senior vice president and sector head for Lonza Biologics as well as vice president for Exclusive Synthesis US. Gemuend joined Lonza in 1988 as legal counsel.
Gemuend holds a law degree from the University of Basel, Switzerland.
Sean A. Johnston, J.D., Ph.D.
Senior Vice President and General Counsel
Sean A. Johnston has been promoted to senior vice president and general counsel, reporting to Stephen G. Juelsgaard, executive vice president, secretary and chief compliance officer. In this role, Johnston is responsible for Genentech's Corporate Law and Intellectual Property groups.
Johnston joined Genentech in 1990 as patent counsel and was promoted to vice president, Intellectual Property in 1998. Prior to joining Genentech, Johnston was law clerk to Judge Wm. Matthew Byrne, Jr. in the U.S. District Court, Central District of California in Los Angeles. Before that, he was a research scientist at International Genetic Engineering, Inc./Xoma Corp.
Johnston holds a Bachelor of Science degree in biochemistry from the University of California, Davis and a doctorate in molecular biology from the University of California, Los Angeles. He also holds a law degree with honors from Stanford Law School.
Timothy L. Moore
Senior Vice President, Global Supply Chain
Timothy L. Moore has been promoted to senior vice president, Global Supply Chain, reporting to Patrick Y. Yang, Ph.D., executive vice president, Product Operations. In this newly created role, Moore is responsible for managing the entire drug production life cycle. In addition to managing the supply chain, Moore will be responsible for Manufacturing Collaborations and Fill/Finish Operations.
Moore joined Genentech in 2004 as vice president, Corporate Engineering and was named vice president, South San Francisco Manufacturing in December 2004. Prior to joining Genentech, Moore served as vice president, Operations at ZLB Behring (formerly Aventis Behring) and managed aseptic/biological manufacturing operations.
Moore holds a Bachelor of Science degree in chemical engineering from the University of Tulsa and a Master of Science degree in engineering management from Northwestern University.
Senior Vice President, Sales and Marketing, BioOncology
John Orwin has been promoted from vice president to senior vice president, Sales and Marketing, BioOncology, reporting to Ian T. Clark, executive vice president, Commercial. In this role, Orwin continues to lead the sales and marketing activities for the BioOncology commercial team, which includes the Avastin® (bevacizumab), HER Family Products, and Rituxan® (Rituximab) businesses.
Orwin joined Genentech in 2005 as vice president, HER Family Product Sales and Marketing, and was promoted to vice president, Sales and Marketing, BioOncology, that same year.
Orwin led the development of the HER (Human EGF-Receptor) Family Product portfolio, including sales and marketing activities as well as the business's life cycle plans. The HER Family includes the oncology products Herceptin® (Trastuzumab) and Tarceva® (erlotinib). Prior to joining Genentech, Orwin served as the franchise vice president, Oncology of the Tibotec Therapeutics group within Johnson & Johnson's Ortho Biotech division.
Orwin holds a Bachelor of Arts degree in economics from Rutgers University and a Master of Business Administration degree from the Stern School of Business, New York University.
Vice President Appointment
Vice President, Planning, Distribution and Logistics
Christopher Horan has been promoted to vice president, Planning, Distribution and Logistics, reporting to Timothy L. Moore, senior vice president, Global Supply Chain. In this role, Horan is responsible for product and materials planning for Genentech's entire supply chain.
Horan joined Genentech in 2004 as senior director, Operational Excellence and most recently held the role of senior director, Supply Chain Operations, Planning and Logistics. Prior to Genentech, Horan held several leadership positions within Merck & Co. Inc., including leadership roles in international manufacturing and the development of Merck's Global Operational Excellence organization.
Horan holds a Bachelor of Engineering degree from the Stevens Institute of Technology in New Jersey.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.